Abstracts tagged "Clinical Osteoporosis"

Abstract Number: 0125 • ACR Convergence 2020
A Resident-Led Interdisciplinary Quality Improvement Initiative to Increase Osteoporosis Screening in an Urban Clinic
Catherine Teskin¹ and Hiba Sayed², ¹Christiana Care, Wilmington, ²Christiana Care, wilmington, DE
Background/Purpose: Osteoporosis is a major cause of morbidity and mortality in the United States. The USPSTF recommends screening all women age 65 and older or…
Abstract Number: 0128 • ACR Convergence 2020
Short-Term Monitoring of Denosumab Effect in Breast Cancer Patients Receiving Aromatase Inhibitors Using Radiofrequency Echographic Multi-Spectrometry (REMS) Technology on Femoral Neck
Rosachiara Forcignanò¹, Fiorella Anna Lombardi², Mariangela Ciccarese³, Eugenio Quarta⁴, Antonella Grimaldi⁵, Laura Quarta⁵, Delia Ciardo², Ernesto Casciaro², Paola Pisani², Francesco Conversano², Maurizio Muratore⁵ and Sergio Casciaro², ¹O.U. of Oncology, “Sacro Cuore di Gesù” Hospital, Gallipoli, Lecce, Italy, Gallipoli, Italy, ²National Research Council, Institute of Clinical Physiology, Lecce, Italy, Lecce, Italy, ³O.U. of Oncology, “Vito Fazzi” Hospital, ASL-LE, Lecce, Italy, Lecce, Italy, ⁴O.U. of Rheumatology, "Galateo" Hospital, ASL-LE, San Cesario di Lecce, Lecce, Italy, San Cesario di Lecce, Italy, ⁵O.U. of Rheumatology, “Galateo” Hospital, San Cesario di Lecce ASL-LE, Lecce, Italy, San Cesario di Lecce, Italy
Background/Purpose: The aim of the study was to carry out a short-term monitoring of the effect of aromatase inhibitors (AI) and Denosumab on bone health…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].